

Fig. S1: Representative pictures of MSTO cells in a colony formation after transfection with microRNA mimics or non coding control (nc) with the indicated concentrations. RRM1 siRNA was used as transfection control.



Fig. S2: Growth inhibition assays of P31 and MSTO cells after transfection with mimics in combination with FGF2 treatment (10 ng/ml) 24 h after mimic transfection (green). In case of FGF2 treatment 96 h after transfection (red), each well was split 1:3 on the day before treatment to avoid complete confluence. Assays were stopped 72 h after FGF2 treatment.

Schelch et al. Fig. S2



Fig. S3: (A) Target gene expression analysis via qPCR 24 h after transfection with FGFR1, FGFR4 or both siRNAs (10 nM) compared to non coding control (nc) in SPC212, P31 and MSTO cells. **(B)** Western blot analysis of FGFR1 (R1) and FGFR4 (R4) knock down in SPC212 cells 72 h after transfection with respective siRNAs.



Fig.S4: Growth inhibition assays of P31 and MSTO cells 72 h after transfection with microRNA mimics (5 nM) and/or siRNAs (10 nM) or respective controls (nc). Predicted values of additive interaction (PV) are indicated as white lines within the black combination bars.

Schelch et al. Fig. S4



Fig.S4: Growth inhibition assays of SPC212, MSTO and P31 cells 72 hours after treatment with PD166866 (PD) or ponatinib (Pon) in combination with obatoclax or venetoclax, or respective controls (co), at the indicated doses.

Schelch et al. Fig. S5